Literature DB >> 29410785

Cooperation between cancer cells.

Marco Archetti1.   

Abstract

Entities:  

Year:  2018        PMID: 29410785      PMCID: PMC5793724          DOI: 10.1093/emph/eoy003

Source DB:  PubMed          Journal:  Evol Med Public Health        ISSN: 2050-6201


× No keyword cloud information.

INTRA-TUMOR COOPERATION

Cancer cells secrete growth factors that induce proliferation, protect against apoptosis and the immune system or promote neo-angiogenesis [1]. As they are diffusible (Fig. 1), the growth factors produced by a cell can be used by other neighbouring cells, an example of cooperation among cancer cells [2].
Figure 1.

A monolayer of producer (blue) and non-producer (yellow) cells of a growth factor with diffusion range d

A monolayer of producer (blue) and non-producer (yellow) cells of a growth factor with diffusion range d A conceptual problem arises: a non-producer cell can exploit the growth factors secreted by its neighbouring producer cells without paying the cost of production; hence non-producers should have a proliferation advantage and spread in the population. How can intra-tumour cooperation be maintained then? Why do not non-producer mutants drive producer cells to extinction?

EVOLUTIONARY PERSPECTIVES

In some cases, two clones producing one growth factor each can coexist if both are essential, because the two clones depend on each other [3], similar to mutualism between species. More in general, in cases without such mutual dependence, a clone producing a growth factor can coexist with a clone producing the same growth factor at a lower (or null) rate if its effect is a sigmoid function of its concentration (which is common for growth factors) [4]: in this case, producer cells have a proliferation advantage at intermediate frequencies—leading to a stable mixed equilibrium of the two types (Fig. 2, right panel). Cooperation collapses if the cost/benefit of the growth factor is high enough (Fig. 2, left panel). The dynamics of growth factor production can be studied using evolutionary game theory and experimental evolution [4].
Figure 2.

Fitness of producer and non-producer cells as a function of the fraction of producer cells for different costs of growth factor production c. Equilibria (full circles: stable; open circles: unstable) and the direction of the dynamics (arrows) are shown

Fitness of producer and non-producer cells as a function of the fraction of producer cells for different costs of growth factor production c. Equilibria (full circles: stable; open circles: unstable) and the direction of the dynamics (arrows) are shown

FUTURE IMPLICATIONS

Targeted therapies aiming at impairing cooperation by blocking growth factors or their receptors [5] are prone to the evolution of resistance. Understanding intra-tumour cooperation is essential to develop evolutionarily stable therapies. An alternative approach could be to use autologous cancer cells in which genes for growth factors have been knocked out [6].
  6 in total

Review 1.  Evolution of cooperation among tumor cells.

Authors:  Robert Axelrod; David E Axelrod; Kenneth J Pienta
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-28       Impact factor: 11.205

2.  Heterogeneity for IGF-II production maintained by public goods dynamics in neuroendocrine pancreatic cancer.

Authors:  Marco Archetti; Daniela A Ferraro; Gerhard Christofori
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-26       Impact factor: 11.205

Review 3.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

4.  Drugs that target pathogen public goods are robust against evolved drug resistance.

Authors:  John W Pepper
Journal:  Evol Appl       Date:  2012-11       Impact factor: 5.183

5.  Evolutionarily stable anti-cancer therapies by autologous cell defection.

Authors:  Marco Archetti
Journal:  Evol Med Public Health       Date:  2013-07-16

6.  Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers.

Authors:  Allison S Cleary; Travis L Leonard; Shelley A Gestl; Edward J Gunther
Journal:  Nature       Date:  2014-04-03       Impact factor: 49.962

  6 in total
  1 in total

1.  Multidrug Cancer Therapy in Metastatic Castrate-Resistant Prostate Cancer: An Evolution-Based Strategy.

Authors:  Jeffrey B West; Mina N Dinh; Joel S Brown; Jingsong Zhang; Alexander R Anderson; Robert A Gatenby
Journal:  Clin Cancer Res       Date:  2019-04-16       Impact factor: 12.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.